3 Smartest Dividend Stocks to Buy Now
When the market entered a correction in February and March,…
Sell
35
MRK Quote, Financials, Valuation and Earnings
Last price:
$86.92
Seasonality move
:
4.06%
Day range:
$88.37 - $90.27
52-week range:
$81.04 - $134.63
Dividend yield:
3.52%
P/E ratio:
13.34x
P/S ratio:
3.55x
P/B ratio:
4.90x
Volume:
15M
Avg. volume:
17.3M
1-year change:
-31.97%
Market cap:
$226.7B
Revenue:
$64.2B
EPS (TTM):
$6.73
Analysts' Opinion
-
Consensus RatingMerck & has received a consensus rating of Buy. The company's average rating is a Buy based on 11 Buy ratings, 10 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $112.07, Merck & has an estimated upside of 24.85% from its current price of $89.76.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $95.00 representing 100% downside risk from its current price of $89.76.
Fair Value
-
According to the consensus of 21 analysts, Merck & has 24.85% upside to fair value with a price target of $112.07 per share.
MRK vs. S&P 500
-
Over the past 5 trading days, Merck & has underperformed the S&P 500 by -1.02% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Merck & does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Merck & has grown year-over-year revenues for 7 quarters straight. In the most recent quarter Merck & reported revenues of $15.6B.
Earnings Growth
-
Merck & earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Merck & reported earnings per share of $1.48.
Enterprise value:
250.2B
EV / Invested capital:
--
Price / LTM sales:
3.55x
EV / EBIT:
11.80x
EV / Revenue:
3.90x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
13.83x
Price / Operating cash flow:
12.60x
Enterprise value / EBITDA:
9.73x
Gross Profit (TTM):
$49B
Return On Assets:
15.29%
Net Income Margin (TTM):
26.68%
Return On Equity:
40.25%
Return On Invested Capital:
21.67%
Operating Margin:
27.83%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $59.3B | $60.1B | $64.2B | $14.6B | $15.6B | |
| Gross Profit | $41.9B | $44B | $49B | $10.7B | $11.8B | |
| Operating Income | $18.3B | $3B | $20.2B | -$1.7B | $4.3B | |
| EBITDA | $21.3B | $6.9B | $25.7B | -$772M | $5.7B | |
| Diluted EPS | $5.71 | $0.14 | $6.73 | -$0.48 | $1.48 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $27.8B | $30.3B | $35.7B | $32.2B | $38.8B | |
| Total Assets | $91.6B | $105.7B | $109.2B | $106.7B | $117.1B | |
| Current Liabilities | $27.3B | $23.9B | $24.2B | $25.7B | $28.4B | |
| Total Liabilities | $66.2B | $67.4B | $63.1B | $69B | $70.7B | |
| Total Equity | $25.4B | $38.3B | $46.1B | $37.6B | $46.4B | |
| Total Debt | $31.8B | $33.1B | $30.7B | $35.1B | $37.1B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $19.1B | $13B | $21.5B | $246M | $3.5B | |
| Cash From Investing | -$5B | -$14.1B | -$7.7B | $53M | -$1.4B | |
| Cash From Financing | -$9.1B | -$4.8B | -$7B | -$2.2B | -$3B | |
| Free Cash Flow | $14.7B | $9.1B | $18.1B | -$743M | $2.5B | |
MRK
Sector
Market Cap
$226.7B
$37M
Price % of 52-Week High
66.67%
43.14%
Dividend Yield
3.52%
0%
Shareholder Yield
3.48%
-1.03%
1-Year Price Total Return
-31.97%
-43.58%
Beta (5-Year)
0.401
0.746
Dividend yield:
3.52%
Annualized payout:
$3.12
Payout ratio:
45.8%
Growth streak:
14 years
Technicals
8-day SMA
Sell
Level
$90.34
200-day SMA
Sell
Level
$107.29
Bollinger Bands (100)
Sell
Level
91.01 - 101.55
Chaikin Money Flow
Buy
Level
704M
20-day SMA
Sell
Level
$92.56
Relative Strength Index (RSI14)
Sell
Level
43.02
ADX Line
Sell
Level
20.4
Williams %R
Neutral
Level
-71.0583
50-day SMA
Sell
Level
$92.33
MACD (12, 26)
Sell
Level
-0.83
25-day Aroon Oscillator
Sell
Level
-48
On Balance Volume
Neutral
Level
704.7M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (4.1386)
Buy
CA Score
(Annual)
Level (0.0398)
Buy
Beneish M-Score
(Annual)
Level (-2.6876)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-2.2238)
Buy
Piotroski F Score
(Annual)
Level (8)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (10)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
Stock Forecast FAQ
In the current month, MRK has received 11 Buy ratings 10 Hold ratings, and 0 Sell ratings. The MRK average analyst price target in the past 3 months is $112.07.
-
Where Will Merck & Stock Be In 1 Year?
According to analysts, the consensus estimate is that Merck & share price will rise to $112.07 per share over the next 12 months.
-
What Do Analysts Say About Merck &?
Analysts are divided on their view about Merck & share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Merck & is a Sell and believe this share price will drop from its current level to $95.00.
-
What Is Merck &'s Price Target?
The price target for Merck & over the next 1-year time period is forecast to be $112.07 according to 21 Wall Street analysts, 11 of them rate the stock a Buy, 0 rate the stock a Sell, and 10 analysts rate the stock a Hold.
-
Is MRK A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Merck & is a Buy. 11 of 21 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of MRK?
You can purchase shares of Merck & via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Merck & shares.
-
What Is The Merck & Share Price Today?
Merck & was last trading at $86.92 per share. This represents the most recent stock quote for Merck &. Yesterday, Merck & closed at $89.76 per share.
-
How To Buy Merck & Stock Online?
In order to purchase Merck & stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
How High Could IBIT Go?
Recently, a surprising number of billionaire hedge fund managers have…
Is Raymond James Stock a Buy, Sell or Hold?
Raymond James Financial (NYSE:RJF) is one of America’s large financial…
Stock Ideas
Buy
56
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
41
Is NVDA Stock a Buy?
Market Cap: $2.6T
P/E Ratio: 37x
Alerts
Buy
80
CORT alert for Apr 1
Corcept Therapeutics [CORT] is down 16.41% over the past day.
Sell
16
PCVX alert for Apr 1
Vaxcyte [PCVX] is down 11.94% over the past day.
Buy
74
COOP alert for Apr 1
Mr. Cooper Group [COOP] is up 4.08% over the past day.
